Domicilium Real Estate Fund III LP 4
4 · Eloxx Pharmaceuticals, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Eloxx (ELOX) 10% Holder Domicilium Acquires 600,000 Shares
What Happened Domicilium Real Estate Fund III LP, a reported 10% holder of Eloxx Pharmaceuticals (ELOX), acquired common stock on June 10, 2026 by exchanging pre‑funded warrants for shares. The filing shows two conversions: 238,422 shares and 361,578 shares, for a total of 600,000 shares. No cash price is reported (transactions listed as N/A) because the shares were issued in exchange for pre‑funded warrants (see F1).
Key Details
- Transaction date: 2026-06-10 (reported on Form 4 filed 2026-06-17).
- Type: Acquisition via exchange of pre‑funded warrants (derivative conversion) (F1).
- Shares acquired: 238,422 and 361,578 (600,000 total). Price: N/A.
- Shares owned after transaction: not specified in the Form 4.
- Notable footnotes: securities are held directly by the Fund and may be indirectly beneficially owned by Domicilium Capital Partners LLC, Domicilium Real Estate Fund III GP LLC, Daniel Simon and related entities (F2–F7). Pre‑funded warrants have no expiration and include a ~19.99% ownership cap on exercise (F5). Reporting persons will be added on subsequent Form 4s once CIKs are received.
- Filing timeliness: No late‑filing indicator shown in this report.
Context This was an institutional conversion of pre‑funded warrants into common stock (not an open‑market purchase or a sale by an officer). For retail investors, note this reflects an institutional holder taking delivery of shares via conversion rather than buying on the market; it does not necessarily signal insider sentiment. The filing also includes typical disclaimers that the reporting entities may only claim pecuniary interests and that additional reporting persons will be listed later.
Insider Transaction Report
- Other
common stock, $0.01 par value per share
[F1][F2]2026-06-10+238,422→ 238,422 total(indirect: See footnote) - Other
common stock, $0.01 par value per share
[F1][F3]2026-06-10+361,578→ 361,578 total(indirect: See footnote) - Other
Pre-funded Warrant
[F5][F1][F2]2026-06-10+238,422→ 0 total(indirect: See footnote)→ common stock, $0.01 par value per share (238,422 underlying) - Other
Pre-funded Warrant
[F5][F1][F3]2026-06-10+361,578→ 834,489 total(indirect: See footnote)→ common stock, $0.01 par value per share (361,578 underlying)
- 14,285(indirect: See footnote)
common stock, $0.01 par value per share
[F4] - 361,578(indirect: See footnote)
Pre-funded Warrant
[F5][F6]→ common stock, $0.01 par value per share (0 underlying) - 611,317(indirect: See footnote)
Pre-funded Warrant
[F5][F7]→ common stock, $0.01 par value per share (0 underlying)
Footnotes (7)
- [F1]Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock.
- [F2]The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.
- [F3]The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.
- [F4]The securities may be deemed to be indirectly beneficially owned by (i) Domicilium, and (ii) Daniel Simon, the managing member of Domicilium.
- [F5]The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.
- [F6]The securities are owned directly by MSEK Charleston LLC ("MSEK") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to MSEK, and (ii) Daniel Simon, the managing member of Domicilium.
- [F7]The securities are owned directly by Bold Stroke Investments, LLC ("Bold Stroke") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to Bold Stroke, and (ii) Daniel Simon, the managing member of Domicilium.